Theravance Biopharma (TBPH)
NASDAQ:TBPH
Holding TBPH?
Track your performance easily

Theravance Biopharma (TBPH) Financial Statements

312 Followers

Theravance Biopharma Financial Overview

Theravance Biopharma's market cap is currently ―. The company's EPS TTM is $-0.923; its P/E ratio is -8.67; Theravance Biopharma is scheduled to report earnings on November 5, 2024, and the estimated EPS forecast is $-0.23. See an overview of income statement, balance sheet, and cash flow financials.
Jun 24Mar 24Dec 23Sep 23Jun 23
Income Statement-
Total Revenue$ 14.26M$ 14.50M$ 17.57M$ 15.69M$ 13.75M
Gross Profit$ 14.26M$ 14.50M$ 17.57M$ 15.69M$ 13.75M
EBIT$ -15.22M$ -9.77M-$ -6.97M$ -13.62M
EBITDA$ -14.24M$ -8.59M---
Net Income Common Stockholders$ -15.88M$ -11.66M$ -8.51M$ -8.95M$ -21.91M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 96.08M$ 99.97M$ 102.43M$ 134.00M$ 167.45M
Total Assets$ 362.03M$ 371.31M$ 382.00M$ 413.59M$ 446.63M
Total Debt$ 46.66M$ 47.90M$ 49.16M$ 50.83M$ 51.68M
Net Debt$ -49.42M$ -52.07M$ -53.27M$ -83.17M$ -115.77M
Total Liabilities$ 168.34M$ 166.44M$ 169.00M$ 167.46M$ 166.47M
Stockholders Equity$ 193.69M$ 204.87M$ 213.00M$ 246.13M$ 280.16M
Cash Flow-
Free Cash Flow$ -4.45M$ -1.11M---
Operating Cash Flow$ -4.42M$ -1.02M$ -854.00K$ -2.49M$ -12.44M
Investing Cash Flow$ -3.03M$ 17.03M$ -677.00K$ -21.00K$ 11.05M
Financing Cash Flow$ -44.00K$ -1.72M$ -30.61M$ -31.40M$ -80.68M
Currency in USD

Theravance Biopharma Earnings and Revenue History

Theravance Biopharma Debt to Assets

Theravance Biopharma Cash Flow

Theravance Biopharma Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis